CBGL (Cannabis Global) EPS without NRI: $-0.02 (TTM As of May. 2022)


What is Cannabis Global EPS without NRI?

Cannabis Global CBGL EPS without NRI is $-0.02 as of May. 2022.

Cannabis Global's earnings per share without non-recurring items for the three months ended in May. 2022 was $-0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in May. 2022 was $-0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cannabis Global's EPS without NRI or its related term are showing as below:

CBGL's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.7
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Cannabis Global's EPS (Diluted) for the three months ended in May. 2022 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in May. 2022 was $-0.02.

Cannabis Global's EPS (Basic) for the three months ended in May. 2022 was $-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in May. 2022 was $-0.02.


Cannabis Global  (OTCPK:CBGL) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cannabis Global EPS without NRI Related Terms


Cannabis Global EPS without NRI Historical Data

* Premium members only.

The historical data trend for Cannabis Global's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannabis Global EPS without NRI Chart

Cannabis Global Annual Data
Trend Aug12 Aug13 Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.02 -0.04 -0.30 -0.16

Cannabis Global Quarterly Data
Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.01 -0.00 -0.01 -0.00

CBGL vs MILC, BBBT, GCAN: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Global's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannabis Global PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Global's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cannabis Global's PE Ratio without NRI falls into.



Cannabis Global EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in May. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.02 mean?
Cannabis Global (CBGL) has a EPS without NRI of $-0.02 as of May. 2022. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cannabis Global and its competitors.
Is Cannabis Global's EPS without NRI too high?
Cannabis Global's current EPS without NRI is $-0.02.
How does Cannabis Global's EPS without NRI compare to MILC and BBBT?
Cannabis Global's EPS without NRI of $-0.02 can be compared against companies in the Drug Manufacturers industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cannabis Global and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Global's current EPS without NRI is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Global stock overvalued right now?
Cannabis Global (CBGL) has a current EPS without NRI of $-0.02. The current EPS without NRI is $-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Cannabis Global (CBGL), the current EPS without NRI is $-0.02 as of May. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannabis Global Business Description

Address 520 S Grand Avenue, Suite 320, Los Angeles, CA, USA, 90071
Cannabis Global Inc manufactures and distributes various cannabis products via its majority ownership of Natural Plant Extract, Inc is developing the Ethos Comply Bag, and generally conducts research and development in the areas of hemp, cannabis and consumer food goods. The company also have an active research and development program focused on creating and commercializing engineered technologies that deliver hemp extracts and cannabinoids to the human body. Its product includes cannabis flower packaged in various weights, cannabis Pre-rolls, cannabis edible products.